This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Kyoto University, Kyowa Kirin Co., Ltd., Kyowa Kirin Co., Ltd.. Active years: 2015-2026.
Company Filing History:
3 out of 868 
1 out of 46 
1 out of 2 Years Active: 2015-2026
Title: The Innovative Contributions of Makoto Taketo
Introduction
Makoto Taketo is a prominent inventor based in Kyoto, Japan. He has made significant advancements in the field of biotechnology, particularly through his research and patent contributions. With a total of three patents to his name, his work is influential in the understanding and treatment of various diseases.
Latest Patents
Makoto Taketo's latest patents reflect his dedication to medical research. One notable patent is the development of an anti-human CCR1 monoclonal antibody. This monoclonal antibody binds to the human CC chemokine receptor 1 (CCR1), inhibiting its activation, which can play a crucial role in treating CCR1-related diseases. Additionally, he has patented a method for determining the prognosis of cancer by detecting phosphorylation of a specific tyrosine residue at position 2681 of TRIO in patient samples. These groundbreaking inventions highlight his commitment to advancing medical science and improving therapeutic strategies.
Career Highlights
Throughout his career, Makoto Taketo has held esteemed positions at leading research institutions. He has been associated with Kyoto University and the Max Delbrück Center for Molecular Medicine. His work in these organizations has allowed him to collaborate with esteemed peers and contribute to critical advancements in medical research.
Collaborations
Collaboration has been a key aspect of Makoto Taketo's work. He has worked alongside colleagues such as Yoshiharu Sakai and Kenji Kawada, combining their expertise to push the boundaries of innovation in biotechnology. These partnerships have fostered a dynamic research environment, resulting in impactful inventions.
Conclusion
In conclusion, Makoto Taketo's inventive contributions, particularly in the field of monoclonal antibodies and cancer prognosis methodologies, have positioned him as a leading figure in biotechnology. His collaborations and commitment to research continue to influence future innovations, promising new possibilities for therapeutic interventions and disease management.